A corrigendum is issued for the article "Integrins in cancer: biological implications and therapeutic opportunities" published in Nature Reviews Cancer 10, 9–22 (2010). The correction concerns a sentence on page 17, in the section "Targeting αβ3 and αβ5". The original sentence was incorrectly phrased and has been revised. The corrected sentence provides additional references and clarifies the development of cilengitide, an inhibitor of both αβ3 and αβ5 integrins. It explains that the authors had previously shown the importance of αβ3 and αβ5 integrins in angiogenesis and tumour growth, and developed a cell-free receptor assay to select for antagonists of these integrins that did not affect αIIbβ3. This assay was used to screen a library of cyclic RGD peptides designed and synthesized by H. Kessler and colleagues for αβ3 activity and selectivity. The corrected sentence also includes references to support these claims. The references provided include studies by Cheresh, Brooks, Aumailley, Gurrath, Pfaff, and Dechantsreiter, which support the findings and development of cilengitide as an integrin inhibitor.A corrigendum is issued for the article "Integrins in cancer: biological implications and therapeutic opportunities" published in Nature Reviews Cancer 10, 9–22 (2010). The correction concerns a sentence on page 17, in the section "Targeting αβ3 and αβ5". The original sentence was incorrectly phrased and has been revised. The corrected sentence provides additional references and clarifies the development of cilengitide, an inhibitor of both αβ3 and αβ5 integrins. It explains that the authors had previously shown the importance of αβ3 and αβ5 integrins in angiogenesis and tumour growth, and developed a cell-free receptor assay to select for antagonists of these integrins that did not affect αIIbβ3. This assay was used to screen a library of cyclic RGD peptides designed and synthesized by H. Kessler and colleagues for αβ3 activity and selectivity. The corrected sentence also includes references to support these claims. The references provided include studies by Cheresh, Brooks, Aumailley, Gurrath, Pfaff, and Dechantsreiter, which support the findings and development of cilengitide as an integrin inhibitor.